19. ライソゾーム病 Lysosomal storage disease Clinical trials / Disease details

臨床試験数 : 854 / 薬物数 : 716 - (DrugBank : 105) / 標的遺伝子数 : 70 - 標的パスウェイ数 : 191

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03018730 (ClinicalTrials.gov)	February 23, 2017	9/1/2017	Safety and Efficacy of PRX 102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)	An Open Label Study of the Safety and Efficacy of PRX 102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)	Fabry Disease	Biological: PRX-102 (pegunigalsidase alfa)	Protalix	NULL	Completed	18 Years	60 Years	All	22	Phase 3	Australia;Canada;Czechia;Germany;Netherlands;Norway;Slovenia;Spain;United Kingdom;Czech Republic
2	NCT02795676 (ClinicalTrials.gov)	June 2016	2/6/2016	Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function	A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta	Fabry Disease	Biological: PRX-102 (pegunigalsidase alfa);Biological: agalsidase beta	Protalix	NULL	Active, not recruiting	18 Years	60 Years	All	78	Phase 3	United States;Argentina;Australia;Belgium;Brazil;Canada;Czechia;Finland;France;Germany;Hungary;Italy;Netherlands;Norway;Paraguay;Slovenia;Spain;Switzerland;Turkey;United Kingdom;Czech Republic
3	NCT01981720 (ClinicalTrials.gov)	December 2013	5/11/2013	Extension Study of PRX-102 for up to 60 Months	A Multi Center Extension Study of PRX-102 Administered by Intravenous Infusions Every 2 Weeks for up to 60 Months to Adult Fabry Patients	Fabry Disease	Biological: PRX-102 (pegunigalsidase alfa)	Protalix	NULL	Completed	18 Years	N/A	All	15	Phase 1/Phase 2	United States;Paraguay;Spain;United Kingdom